组蛋白去乙酰化酶抑制剂在乳腺癌中的研究进展  

Research progress of histone deacetylase inhibitors in breast cancer

作　　者：杜亚楠 李茹恬[2] 谢丽[2] DU Yanan;LI Rutian;XIE Li(Medical School of Nanjing University,Jiangsu Nanjing 210093,China;Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Jiangsu Nanjing 210008,China)

机构地区：[1]南京大学医学院,江苏南京210093 [2]南京大学医学院附属鼓楼医院,江苏南京210008

出　　处：《现代肿瘤医学》2024年第24期4674-4679,共6页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:82272852)。

摘　　要：乳腺癌是女性高发癌症,严重危害妇女身体健康。组蛋白去乙酰化酶(histone deacetylase,HDAC)能够调控人体组蛋白乙酰化与去乙酰化之间的关系,从而调节细胞增殖等表型。既往研究提示组蛋白乙酰化状态的异常表现与乳腺癌的发生发展有关。该文综述了去乙酰化酶抑制剂(histone deacetylase inhibitors,HDACi)在乳腺癌治疗中的研究进展,通过深入了解去乙酰化酶抑制剂的作用机制及其在乳腺癌治疗中的应用,发现去乙酰化酶抑制剂在乳腺癌的治疗中展现出了良好的应用前景。该文旨在探讨去乙酰化酶抑制剂的作用机制、临床试验结果以及对乳腺癌治疗的影响,为该类药物未来在乳腺癌中的应用寻找方向。Breast cancer is a common cancer in women and poses a serious threat to women's health.Histone deacetylase(HDAC)can regulate the relationship between acetylation and deacetylation of histones in the human body,thereby regulating cell proliferation and other phenotypes.Previous studies have suggested that abnormal histone acetylation is associated with the occurrence and development of breast cancer.This article reviews the research progress of histone deacetylase inhibitors(HDACi)in the treatment of breast cancer.By deeply understanding the mechanism of action of histone deacetylase inhibitors and their application in the treatment of breast cancer,it is found that histone deacetylase inhibitors have shown promising prospects in the treatment of breast cancer.The aim of this article is to explore the mechanism of action of histone deacetylase inhibitors,clinical trial results,and their impact on the treatment of breast cancer,providing directions for the future application of these drugs in the treatment of breast cancer.

关 键 词：组蛋白去乙酰化酶抑制剂(HDACi) 去乙酰化 原发性乳腺癌 西达本胺 

分 类 号：R737.9[医药卫生—肿瘤]